These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 27393516)

  • 1. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases.
    Dudnik E; Yust-Katz S; Nechushtan H; Goldstein DA; Zer A; Flex D; Siegal T; Peled N
    Lung Cancer; 2016 Aug; 98():114-117. PubMed ID: 27393516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.
    Gion M; Remon J; Caramella C; Soria JC; Besse B
    Lung Cancer; 2017 Jun; 108():72-74. PubMed ID: 28625652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
    Fujimoto D; Morimoto T; Ito J; Sato Y; Ito M; Teraoka S; Otsuka K; Nagata K; Nakagawa A; Tomii K
    Lung Cancer; 2017 Sep; 111():1-5. PubMed ID: 28838377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
    Crinò L; Bronte G; Bidoli P; Cravero P; Minenza E; Cortesi E; Garassino MC; Proto C; Cappuzzo F; Grossi F; Tonini G; Sarobba MG; Pinotti G; Numico G; Samaritani R; Ciuffreda L; Frassoldati A; Bregni M; Santo A; Piantedosi F; Illiano A; De Marinis F; Tamberi S; Giannarelli D; Delmonte A
    Lung Cancer; 2019 Mar; 129():35-40. PubMed ID: 30797489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
    Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
    Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracranial complete response for non-small-cell lung cancer patient with negative PD-L1 expression of the lung using nivolumab.
    Kitadai R; Zenke Y; Hishima T; Hosomi Y
    Cancer Rep (Hoboken); 2022 Feb; 5(2):e1460. PubMed ID: 34042323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.
    Gauvain C; Vauléon E; Chouaid C; Le Rhun E; Jabot L; Scherpereel A; Vinas F; Cortot AB; Monnet I
    Lung Cancer; 2018 Feb; 116():62-66. PubMed ID: 29413052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer.
    De Braganca KC; Janjigian YY; Azzoli CG; Kris MG; Pietanza MC; Nolan CP; Omuro AM; Holodny AI; Lassman AB
    J Neurooncol; 2010 Dec; 100(3):443-7. PubMed ID: 20440540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
    Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
    Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
    Ruiz-Bañobre J; Pérez-Pampín E; García-González J; Gómez-Caamaño A; Barón-Duarte FJ; López-López R; Vázquez-Rivera F
    Lung Cancer; 2017 Jun; 108():217-221. PubMed ID: 28625638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment.
    Kimura H; Sone T; Murata A; Koba H; Tambo Y; Hara J; Abo M; Kasahara K
    Lung Cancer; 2017 Jun; 108():7-8. PubMed ID: 28625651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.
    Tanvetyanon T; Creelan BC; Antonia SJ
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):903-10. PubMed ID: 27488231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
    Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
    Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
    Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L
    J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of brain metastases response to immunotherapy with pembrolizumab.
    Mahajan A; Goldberg SL; Weiss SA; Tran T; Singh K; Joshi K; Aboian MS; Kluger HM; Chiang VL
    J Neurooncol; 2024 Sep; 169(3):555-561. PubMed ID: 38963658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
    Dudnik E; Moskovitz M; Daher S; Shamai S; Hanovich E; Grubstein A; Shochat T; Wollner M; Bar J; Merimsky O; Zer A; Goldstein DA; Hammerman A; Cyjon A; Shechtman Y; Abu-Amna M; Flex D; Roisman LC; Peled N;
    Lung Cancer; 2018 Dec; 126():217-223. PubMed ID: 29254746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
    Grossi F; Genova C; Crinò L; Delmonte A; Turci D; Signorelli D; Passaro A; Soto Parra H; Catino A; Landi L; Gelsomino F; Tiseo M; Puppo G; Roila F; Ricciardi S; Tonini G; Cognetti F; Toschi L; Tassinari D; Scoppola A; Giannarelli D; Cortesi E
    Eur J Cancer; 2019 Dec; 123():72-80. PubMed ID: 31671314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic effect of nivolumab on non-small-cell lung cancer patients with brain metastases: a retrospective study].
    Zhang GW; Cheng RR; Wang HJ; Zhang Y; Li P; Yan XT; Zhang MN; Zhang XJ; Yang JP; Ma ZY
    Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):961-965. PubMed ID: 33256309
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.